Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $22.56

by · The Cerbat Gem

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $22.5556.

Several equities research analysts have recently commented on OCUL shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, November 5th. HC Wainwright increased their price target on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Cowen restated a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Finally, Piper Sandler raised their target price on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd.

Read Our Latest Research Report on Ocular Therapeutix

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its holdings in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 893 shares during the period. Trust Co. of Vermont increased its stake in shares of Ocular Therapeutix by 16.1% in the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,000 shares in the last quarter. Quarry LP bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $80,000. Finally, Marex Group plc purchased a new position in shares of Ocular Therapeutix during the 2nd quarter valued at $115,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Performance

OCUL stock opened at $11.26 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. Ocular Therapeutix has a 1 year low of $5.78 and a 1 year high of $16.44. The company has a market cap of $2.40 billion, a P/E ratio of -7.82 and a beta of 0.93. The stock’s fifty day moving average price is $12.32 and its 200-day moving average price is $11.96.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The company had revenue of $14.54 million during the quarter, compared to analysts’ expectations of $14.57 million. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%. On average, equities analysts forecast that Ocular Therapeutix will post -0.98 earnings per share for the current year.

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

Further Reading